P. Mehta

First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model

Findings provide a mechanistic rationale for further clinical development of APG157DS in GBM and potentially other immune-evasive cancers.